Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Aytu Biopharma (AYTU) over the last 11 years, with Q4 2025 value amounting to -$609000.0.

  • Aytu Biopharma's Change in Inventory rose 287.08% to -$609000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.1 million, marking a year-over-year decrease of 15284.67%. This contributed to the annual value of -$382000.0 for FY2025, which is 10792.37% down from last year.
  • Per Aytu Biopharma's latest filing, its Change in Inventory stood at -$609000.0 for Q4 2025, which was up 287.08% from -$1.1 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Change in Inventory registered a high of $2.1 million during Q3 2022, and its lowest value of -$7.2 million during Q2 2021.
  • For the 5-year period, Aytu Biopharma's Change in Inventory averaged around -$70800.0, with its median value being $284000.0 (2021).
  • Per our database at Business Quant, Aytu Biopharma's Change in Inventory skyrocketed by 108202.25% in 2022 and then tumbled by 21616.77% in 2025.
  • Over the past 5 years, Aytu Biopharma's Change in Inventory (Quarter) stood at $390000.0 in 2021, then plummeted by 79.74% to $79000.0 in 2022, then surged by 765.82% to $684000.0 in 2023, then plummeted by 191.67% to -$627000.0 in 2024, then rose by 2.87% to -$609000.0 in 2025.
  • Its Change in Inventory stands at -$609000.0 for Q4 2025, versus -$1.1 million for Q3 2025 and $518000.0 for Q2 2025.